- $12.45m
- $3.86m
- $5.21m
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer
Brief: Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
U.S. STOCKS ON THE MOVE-Wendy's, Canadian Solar, Bio-Techne
Plus Therapeutics up after unit signs deal with Elevance Health for cancer test
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
Brief: Plus Therapeutics - May Offer And Sell Up To $100 Million Of Securities From Time To Time - SEC Filing
Plus Therapeutics Q1 net loss narrows
Brief: Plus Therapeutics Announces Oral Presentation Highlighting Reyobiq™ Clinical And Translational Data Demonstrating Favorable Safety, Survival, And Emerging Immunomodulation In Leptomeningeal Metastases
Brief: Plus Therapeutics Receives Medicare Enrollment Approval For Cnside Diagnostic
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Plus Therapeutics rises as FDA grants orphan drug tag for pediatric brain cancer treatment
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple